Patient group input requested for a new Joint Assessment on a medicinal product for acute myeloid leukaemia (AML).
EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique knowledge about what it is like to live with a specific disease or medical condition. We
PTJA14 – Pretomanid in combination with bedaquiline and linezolid in adults for the treatment of pulmonary extensively drug-resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB) – Final assessment now available
This is the pharmaceutical Joint Assessment PTJA14 – Pretomanid in combination with bedaquiline and linezolid in adults for the treatment of pulmonary extensively drug-resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). In August, 2020, the European Commission granted marketing
RCR01-RCR15 Covid-19 Rolling Collaborative Review – Second round of reviews now available
As part of its response to the Covid-19 pandemic, EUnetHTA is working to output 'Rolling Collaborative Reviews (RCR)'. The objective of such reviews is to provide decision-makers with a timely synthesis of available evidence on the comparative effectiveness of therapeutic
OTCA26 Obesity Surgery Project – Project Plan now available
EUnetHTA is pleased to announce the project description and planning for 26th Other Technologies Collaborative Assessment "Surgical procedures for treatment of obesity" is now available for access. The relevance of the topic lies in evidence suggesting that bariatric surgery decreases the
Final Week – EUnetHTA Open Call for Early Dialogue Requests
The EUnetHTA ED Secretariat is holding an Open Call to fill the slots available for EDs through May 31, 2021. EUnetHTA will aim to conduct 1 ED per month with a maximum 8 EDs during the EUnetHTA prolongation period. The Open
RCROT02 – Rapid Collaborative Review on the diagnostic accuracy of molecular methods that detect the presence of SARS-CoV-2 virus in people with suspected COVID-19 – Project Plan now available
EUnetHTA is pleased to announce the publication of the final project plan of its Rapid Collaborative Review on the diagnostic accuracy of molecular methods that detect the presence of SARS-CoV-2 virus in people with suspected COVID-19. This is the second one of
OTCA23 Final Assessment Report “Biodegradable rectum spacers to reduce toxicity for prostate cancer” now available
The Other Technologies Collaborative Assessment OTCA23 final assessment report "Biodegradable rectum spacers to reduce toxicity for prostate cancer'', together with related documentation, is now available for access. The assessed technology is biodegradable rectum spacers added to conventional radiotherapy to (temporarily) position
OTCA27 – Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia (BPH)- project plan now available
The final project plan of the assessment on “Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia (BPH)” is now available. Comments from external experts and answers of the Authoring Team are also accessible. This
PTJA12 – Glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy – Final assessment now available
This is the pharmaceutical Joint Assessment PTJA12 - on glasdegib for the treatment of acute myeloid leukaemia (AML). In June 2020, the European Commission granted marketing authorisation for Daurismo® (glasdegib), in combination with low-dose cytarabine, for the treatment of newly
PTJA10 – crizanlizumab indicated for the prevention of recurrent vast-occlusive crises in sickle cell disease patients aged 16 years and over – project plan now available
The final project plan of the relative effectiveness assessment of 'crizanlizumab indicated for the prevention of recurrent vast-occlusive crises in sickle cell disease patients aged 16 years and over' is now available for access. The final assessment report will be